Differentiating purely viral from bacterial etiologies continues to be a challenging yet key step in the management of community-acquired pneumonia (CAP), further highlighted since the COVID-19 pandemic. This study aims to evaluate the utility of 99mTc-ubiquicidin (UBI) in the differentiation of bacterial from nonbacterial pneumonia.
Methods:
A total of 30 patients with CAP were allocated into groups A, bacterial (n = 15), and B, viral pneumonia (n = 15). All patients underwent 99mTc-UBI scan with planar and single-photon emission computed tomography (SPECT) images of thorax acquired at 30 and 180 min postinjection. Target-to-background (T/B) ratios were calculated with values >1.4 interpreted as positive for bacterial infection. Correlation was made with computed tomography (CT) scan and polymerase chain reaction (PCR) results.
Results:
UBI scan was positive in 43.3% (n = 13) of patients, with sensitivity, specificity, and accuracy of 86.7%, 100%, and 93.3%, respectively, and close correlation with chest CT scan and PCR results (p-value = 0.000). Planar images were generally not helpful. Receiver operating characteristic curve analysis indicated similar diagnostic performance for 30-min and 3-h SPECT images by implementing T/B thresholds of 1.2 and 1.33, respectively.
Conclusions:
99mTc-UBI SPECT is a promising modality for differentiating purely viral from bacterial or superimposed bacterial pneumonia and provides reliable evidence either to mandate or withhold administration of antibiotics in patients with CAP.
JainS. Epidemiology of viral pneumonia. Clin Chest Med, 2017; 38(1):1–9.
3.
RuuskanenO, LahtiE, JenningsLC, et al.Viral pneumonia. Lancet, 2011; 377(9773):1264–1275.
4.
PrattMT, AbdallaT, RichmondPC, et al.Prevalence of respiratory viruses in community-acquired pneumonia in children: A systematic review and meta-analysis. Lancet Child Adolesc Health, 2022; 6(8):555–570.
5.
TorresA, CillónizC, TorresA, et al.Epidemiology, Etiology, and Risk Factors of Bacterial Pneumonia. Springer; 2015; 7–28.
6.
AlsharifW, QurashiA. Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography (Lond), 2021; 27(2):682–687.
7.
TsouP-Y, RafaelJ, MaY-K, et al.Diagnostic accuracy of procalcitonin for bacterial pneumonia in children–a systematic review and meta-analysis. Infect Dis (Lond), 2020; 52(10):683–697.
8.
ZhengF, LiL, ZhangX, et al.Accurately discriminating COVID-19 from viral and bacterial pneumonia according to CT images via deep learning. Interdiscip Sci Comput Life Sci, 2021; 13(2):273–285.
9.
SongY, ZhengS, LiL, et al.Deep learning enables accurate diagnosis of novel coronavirus (COVID-19) with CT images. IEEE/ACM Trans Comput Biol Bioinform, 2021; 18(6):2775–2780.
10.
XuX, JiangX, MaC, et al.A deep learning system to screen novel coronavirus disease 2019 pneumonia. Engineering (Beijing), 2020; 6(10):1122–1129.
11.
BaiHX, WangR, XiongZ, et al.Artificial intelligence augmentation of radiologist performance in distinguishing COVID-19 from pneumonia of other origin at chest CT. Radiology, 2020; 296(3):E156–E165.
12.
ElmokademAH, BayoumiD, Abo-HedibahSA, et al.Diagnostic performance of chest CT in differentiating COVID-19 from other causes of ground-glass opacities. Egypt J Radiol Nucl Med, 2021; 52(1):1–10.
13.
ChongWH, SahaBK, RamaniA, et al.State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. Infection, 2021; 49(4):591–605.
14.
MeterskyML, MastertonRG, LodeH, et al.Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis, 2012; 16(5):e321–e331.
15.
AkhtarMS, QaisarA, IrfanullahJ, et al.Antimicrobial peptide 99mTc-ubiquicidin 29–41 as human infection-imaging agent: Clinical trial. J Nucl Med, 2005; 46(4):567–573.
16.
ShintoAS, MukherjeeA, KaruppusamyKK, et al.Clinical utility of 99mTc-ubiquicidin (29–41) as an adjunct to bone scan in differentiating infected versus noninfected loosening of prosthesis before revision surgery. Nuclear Med Commu, 2017; 38(4):285–290.
17.
AyatiN, NorouziM, SadeghiR, et al.Diagnostic value of 99mTc-ubiquicidin scintigraphy in differentiation between osteomyelitis and bone tumors. Nucl Med Commun, 2017; 38(11):885–890.
18.
BeikiD, YousefiG, FallahiB, et al.99mtc-Ubiquicidin [29–41], a promising radiopharmaceutical to differentiate orthopedic implant infections from sterile inflammation. Iranian J Pharm Res, 2013; 12(2):347.
19.
AssadiM, VahdatK, NabipourI, et al.Diagnostic value of 99mTc-ubiquicidin scintigraphy for osteomyelitis and comparisons with 99mTc-methylene diphosphonate scintigraphy and magnetic resonance imaging. Nucl Med Commun, 2011; 32(8):716–723.
20.
SaeedS, ZafarJ, KhanB, et al.Utility of 99m Tc-labelled antimicrobial peptide ubiquicidin (29-41) in the diagnosis of diabetic foot infection. Eur J Nucl Med Mol Imaging, 2013; 40(5):737–743.
21.
VatakaraA, DamleNA, KhuranaA, et al.99mTechnetium-ubiquicidin scan with single-photon emission computed tomography/computed tomography in skull base osteomyelitis. Indian J Nucl Med, 2023; 38(3):297–300.
22.
Marjanovic-PainterB, KleynhansJ, ZeevaartJR, et al.A decade of ubiquicidin development for PET imaging of infection: A systematic review. Nucl Med Biol, 2023; 116–117:108307.
23.
ThakralP, RanaN, SinghN, et al.Validation of radiosynthesis and first in-human dosimetry of 68Ga-NOTA-UBI-29-41: A proof of concept study. Cancer Biother Radiopharm, 2024.
24.
NogueiraSA, de BarbozaMF, Dell’AquilaAM, et al.Could 68Ga-DOTA-UBI-29-41 help identify chronic osteomyelitis on PET/CT images? A Pilot Study. Clin Nucl Med, 2023; 48(11):982–984.
25.
MirandaACC, de Paula SantosCR, FuscaldiLL, et al.68GA-NOTA-UBI AND 68GA-DOTA-UBI as radiopharmaceuticals for the diagnosis of infectious processes: Preclinical studies and translation to clinical application. Hematology, Transfusion and Cell Therapy, 2024; 46:S2–S3.
26.
GhodsiradMA, AryanaK, SaminiF, et al.Diagnostic value of 99m Tc-labeled-ubiquicidin 29-41 (99m Tc-UBI) scan in the diagnosis of vertebral osteomyelitis. Cmir, 2018; 14(6):906–913.
27.
AfzalZ, MinardCG, StagerCE, et al.Clinical diagnosis, viral PCR, and antibiotic utilization in community-acquired pneumonia. Am J Ther, 2016; 23(3):e766–e772.
28.
SathekgeM, Garcia-PerezO, PaezD, et al.Molecular imaging in musculoskeletal infections with 99m Tc-UBI 29-41 SPECT/CT. Ann Nucl Med, 2018; 32(1):54–59.
29.
AtifM, HussainF, DarZS, et al.Diagnostic accuracy of 99 MTC labelled Ubiquicidin (29-41) Spect/CT for diagnosis of osteomyelitis in diabetic foot. Pafmj, 2021; 71(3):1015–1019.
30.
ZavadovskayaV, LarkinaM, StasyukE, et al.Radiolabeled complex of antimicrobial peptides UBI29-41 and UBI18-35 labeled with 99m Tc for differential diagnosis of bone infection of the limbs. Bull Exp Biol Med, 2021; 170(4):415–419.
31.
VallejoE, MartinezI, TejeroA, et al.Clinical utility of 99mTc-labeled ubiquicidin 29–41 antimicrobial peptide for the scintigraphic detection of mediastinitis after cardiac surgery. Arch Med Res, 2008; 39(8):768–774.
32.
QuirceR, CarrilJ, Gutiérrez-MendiguchíaC, et al.Assessment of the diagnostic capacity of planar scintigraphy and SPECT with 99mTc-HMPAO-labelled leukocytes in superficial and deep sternal infections after median sternotomy. Nucl Med Commun, 2002; 23(5):453–459.
PaezD, SathekgeMM, DouisH, et al.Comparison of MRI,[18 F] FDG PET/CT, and 99m Tc-UBI 29-41 scintigraphy for postoperative spondylodiscitis—a prospective multicenter study. Eur J Nucl Med Mol Imaging, 2021; 48(6):1864–1875.
35.
ZhouJ, LiaoX, CaoJ, et al.Differential diagnosis between the coronavirus disease 2019 and Streptococcus pneumoniae pneumonia by thin-slice CT features. Clin Imaging, 2021; 69:318–323.
36.
FranquetT. Imaging of community-acquired pneumonia. J Thorac Imaging, 2018; 33(5):282–294.
37.
KangM, HongKS, ChikontweP, et al.Quantitative assessment of chest CT patterns in COVID-19 and bacterial pneumonia patients: A deep learning perspective. J Korean Med Sci, 2021; 36(5):e46.
FangY, ZhangH, XieJ, et al.Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. Radiology, 2020; 296(2):E115–E117.
40.
XieX, ZhongZ, ZhaoW, et al.Chest CT for typical coronavirus disease 2019 (COVID-19) pneumonia: Relationship to negative RT-PCR testing. Radiology, 2020; 296(2):E41–E45.
41.
KamatIS, RamachandranV, EswaranH, et al.Procalcitonin to distinguish viral from bacterial pneumonia: A systematic review and meta-analysis. Clin Infect Dis, 2020; 70(3):538–542.
42.
ThomasJ, PociuteA, KevalasR, et al.Blood biomarkers differentiating viral versus bacterial pneumonia aetiology: A literature review. Ital J Pediatr, 2020; 46(1):4–10.
43.
HuangI, PranataR, LimMA, et al.C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis. Ther Adv Respir Dis, 2020; 14:1753466620937175.
